Neurocrine Biosciences, Inc’s recent filing unveils that its Chief Scientific Officer Onyia Jude unloaded Company’s shares for reported $0.29 million on Nov 29 ’24. In the deal valued at $126.29 per share,2,331 shares were sold. As a result of this transaction, Onyia Jude now holds 15,449 shares worth roughly $1.98 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, JUDE ONYIA bought 2,331 shares, generating $295,081 in total proceeds.
Before that, Boyer David W. sold 3,461 shares. Neurocrine Biosciences, Inc shares valued at $421,828 were divested by the Chief Corp. Affairs Officer at a price of $121.88 per share. As a result of the transaction, Boyer David W. now holds 1,672 shares, worth roughly $0.21 million.
A number of analysts have revised their coverage, including Piper Sandler’s analysts, who increased its forecast for the stock in late August from “a Neutral” to “an Overweight”. Wells Fargo also remained covering NBIX and has increased its forecast on April 24, 2024 with a “an Overweight” recommendation from previously “an Equal weight” rating.
Price Performance Review of NBIX
On Friday, Neurocrine Biosciences, Inc [NASDAQ:NBIX] saw its stock jump 1.36% to $128.14. Over the last five days, the stock has gained 1.10%. Neurocrine Biosciences, Inc shares have fallen nearly -2.75% since the year began. Nevertheless, the stocks have risen 7.26% over the past one year. While a 52-week high of $157.98 was reached on 08/01/24, a 52-week low of $110.95 was recorded on 10/03/24. SMA at 50 days reached $120.10, while 200 days put it at $133.12.
Levels Of Support And Resistance For NBIX Stock
The 24-hour chart illustrates a support level at 127.09, which if violated will result in even more drops to 126.04. On the upside, there is a resistance level at 129.06. A further resistance level may holdings at 129.98. The Relative Strength Index (RSI) on the 14-day chart is 59.95, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.24, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 5.78%. Stochastics %K at 91.97% indicates the stock is a selling.
How much short interest is there in Neurocrine Biosciences, Inc?
A steep rise in short interest was recorded in Neurocrine Biosciences, Inc stocks on 2024-11-15, growing by 1.62 million shares to a total of 4.24 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 2.62 million shares. There was a rise of 38.22%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 12, 2023 when Deutsche Bank began covering the stock and recommended ‘”a Buy”‘ rating along with a $136 price target.
